Phase 1 clinical trial results for Ceritinib have revealed affirmative results, leading the FDA to grant an accelerated approval for this impressive drug. Deemed to be “highly active” in the fight against ALK-rearranged non-small-cell lung cancer, Ceritinib is also twenty times more potent than Crizotinib. The exciting results from Novartis’s Phase 1 trial were recently[…]
FDA Grants Accelerated Approval to Ceritinib For ALK- Positive NSCLC
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, FDA Approved 2014 Tags: Crizotinib Jun 09, 2014
Crizotinib FDA approval benefits ALK-positive NSCLC patients
Chemotherapeutic / Anti-Neoplastic, FDA Approved 2011 Tags: Crizotinib Nov 27, 2013
On November 21, 2013 the FDA announced the approval of the formidable cancer drug Crizotinib to treat ALK-positive tumors. Patients with metastatic non-small cell lung cancer who have anaplastic lymphoma kinase (ALK)-positive tumors stand to benefit greatly from the Crizotinib FDA approval. Encouraging data that demonstrated efficacious progression-free survival propelled the Crizotinib FDA approval decision. In 2011[…]
Crizotinib Offers Hope for Patients with a Rare Form of Non-Small Cell Lung Cancer
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API Tags: Crizotinib Jun 19, 2012
Crizotinib, CAS number 877399-52-5, is also known as the brand Xalkori. Xalkori, manufactured Pfizer, was approved on August 26, 2011 by the FDA for metastatic non-small cell lung cancer. Crizotinib is ideal for patients who have a certain type of chromosome translocation, specifically one that affects the anaplastic lymphoma kinase, or ALK gene, which causes[…]
